Is your rare disease strategy keeping pace with a rapidly shifting access landscape?
Rare disease has always demanded rigorous evidence and careful payer navigation. But expectations are accelerating. Scrutiny is intensifying, evidence bars are rising, and the pricing precedents being set today will shape access decisions for years to come.
This webinar takes a therapy area-specific look at how payer and HTA expectations are evolving across rare diseases, and what that means for access teams shaping strategy right now.
